Study investigates the relationship between dietary inflammatory index and stroke risk in US adults

In trials, the product reduced itch and sleep disturbance within the first four weeks of treatment. Credit: Dermatology11/Shutterstock. The US Food and Drug Administration (FDA)

Fol­low­ing quick­ly on the heels of US biosim­i­lar ap­provals, Am­s­ter­dam-based Pol­phar­ma Bi­o­log­ics scored a Eu­ro­pean Com­mis­sion au­tho­riza­tion for its Tysabri (na­tal­izum­ab) biosim­i­lar for mul­ti­ple scle­ro­sis,